By inhibiting C3 and C3b, pegcetacoplan may prevent excessive glomerular deposition of C3 and C5 breakdown products and the ensuing glomerular inflammation and renal damage observed in this disease (Figure 1), which in turn may translate to improved clinical outcomes.19, 20, 21 Therefore, the objective of this phase 2 DISCOVERY study was to investigate the preliminary efficacy and safety of pegcetacoplan over 48 weeks as a potential treatment for patients with the complement-mediated glomerular diseases of C3G, IgAN, LN, and PMN. The gene discussed is C5; the disease is complement 3 glomerulopathy.